How insulin stimulates postprandial uptake of glucose and long-chain fatty acids (LCFAs) into skeletal muscle and the mechanisms by which these events are dampened in diet-induced obesity are incompletely understood. Here, we show that RalGAP1 is a critical regulator of muscle insulin action and governs both glucose and lipid homeostasis. A high-fat diet increased RalGAP1 protein but decreased its insulin-responsive Thr 735 -phospho rylation in skeletal muscle. A RalGAP1
INTRODUCTION
Type 2 diabetes (T2D) has become prevalent worldwide in recent decades because of changes in diet and lifestyle. Insulin resistance lessens the responses of target tissues to insulin stimulation and underlies the pathogenesis of T2D (1) . Therefore, better understanding of insulin action and molecular basis for insulin resistance are key for drug development to combat T2D.
The skeletal muscle is the largest insulin-sensitive organ in the body and plays a key role in regulating postprandial glucose and lipid homeostasis (2, 3) . When insulin binds to its receptor, it activates the receptor tyrosine kinase, resulting in tyrosine phosphorylation of insulin receptor substrates (IRSs), which in turn initiate signaling via the phosphatidylinositol 3-kinase-protein kinase B (PKB) (also known as Akt) signaling pathway that controls muscle glucose and lipid homeostasis (4) . The insulin-PKB pathway also regulates protein synthesis via the tuberous sclerosis complex protein 1 and 2 (TSC1/2)-mammalian target of rapamycin complex 1 (mTORC1) signaling axis (5) . mTORC1 and its downstream target, ribosomal protein S6 kinase (S6K), can phosphorylate IRS on multiple serine residues, which inhibits tyrosine phosphorylation of IRS, providing feedback mechanisms that may prevent overactivation of the insulin signaling pathway (6) . In diet-induced obesity, fatty acids can activate a number of kinases, including mTORC1, c-Jun N-terminal kinase (JNK), and PKC, which also phosphorylate serine residues in IRS and dampen insulin signaling (6) . These changes in obesity provide a molecular basis for diet-induced muscle insulin resistance. However, it is currently unclear whether further IRS-independent mechanisms might contribute to development of muscle insulin resistance.
TSC1 and TSC2 form a guanosine triphosphatase (GTPase) activating protein (GAP) complex in which TSC2 is a catalytic subunit having GAP activity toward the small heterotrimeric guanosine 5′-triphosphate (GTP)-binding protein (G protein) Rheb and TSC1 is a regulatory subunit (7) . Inactivation of the GAP of TSC1/2, for example, in response to insulin, promotes GTP loading and activation of Rheb and hence activates mTORC1. The TSC1/2 complex shares sequence and structural similarity with a RalGAP complex that consists of a catalytic RalGAP subunit and a regulatory RalGAP subunit (8, 9) . The RalGAP complex can stimulate GTP hydrolysis by two related small G proteins, namely, RalA and RalB (8) . Active GTP-loaded RalA promotes docking of glucose transporter 4 (GLUT4) storage vesicles onto the plasma membrane through interaction with the exocyst and thereby regulates GLUT4 translocation in cultured adipocytes and muscle cells (10, 11) . GTP-loaded RalB engages with the exocyst to activate mTORC1 (12) , which suggests that the RalGAP complex might be involved in feedback regulation of IRS serine phosphorylation. In contrast to the single TSC1/2 complex, two RalGAP complexes exist in mammalian cells, in which catalytic subunits RalGAP1 and RalGAP2, respectively, bind to the common regulatory RalGAP subunit (8) . The RalGAP1/ complex is dominant in skeletal muscle, while RalGAP2/ is the major complex in adipose tissues (13) . RalGAP1 is phosphorylated on its Thr 735 by PKB in response to insulin, which results in its inactivation in rat L6 muscle cells. Inactivation of RalGAP1 by Thr 735 phosphorylation increases GTP-loaded active RalA that promotes translocation of GLUT4 from intracellular storage sites onto the plasma membrane in response to insulin (13) . These findings in rat L6 muscle cells suggest a possible role for RalGAP1 in mediating muscle insulin action. However, its exact roles in insulin action and resistance in skeletal muscle remain to be defined.
Here, we used mouse models to investigate the physiological and pathophysiological relevance of RalGAP1 in muscle insulin action and resistance. Furthermore, we developed a strategy to target RalGAP1 in muscle cells for improving insulin sensitivity. RalGAP2 on the endogenous proteins by this antibody was further confirmed in L6 myotubes and primary hepatocytes through downregulation of these two proteins (fig. S1, C to E). Using this antibody, we found that Thr 735 phosphorylation of RalGAP1 was markedly diminished in skeletal muscle that was insulin resistant because of PKB deficiency ( fig. S2A ). High-fat diets (HFDs) are well-known to induce muscle insulin resistance, and we investigated their effects on RalGAP1/ in skeletal muscle of diet-induced obese (DIO) mice. As expected, insulin-stimulated PKB phosphorylation was impaired in skeletal muscle of DIO mice (Fig. 1A and fig. S2B ). The protein levels of RalGAP1 and RalGAP subunits were both substantially increased, while their mRNA levels were unaltered in skeletal muscle of DIO mice (Fig. 1A and fig. S2F ). RalGAP1-Thr 735 phosphorylation was increased in skeletal muscle of mice fed with a normal chow diet upon insulin stimulation, while this phosphorylation was significantly lower in skeletal muscle of DIO mice under both basal and insulin conditions ( Fig. 1A and fig. S2C ). As a consequence, the GTP-bound active forms of RalA and RalB were notably decreased in skeletal muscle of DIO mice despite their normal mRNA and protein levels ( Fig. 1A and fig. S2 , D to F). In agreement with these findings, we found that, in differentiated L6 myotubes, oleic acid (OA) decreased insulin-stimulated PKB phosphorylation in concomitance with an elevation of IRS1-Ser 307 phosphorylation (Fig. 1B  and fig. S2 , G and H). OA treatment increased RalGAP1 and RalGAP protein levels without affecting their mRNA levels and impaired RalGAP1-Thr 735 phosphorylation (Fig. 1B and fig. S2 , I and K). OA treatment lowered the levels of active RalA and RalB in L6 myotubes (Fig. 1B and fig. S2 , J and L) and concurrently impaired insulinstimulated uptake of glucose and long-chain fatty acids (LCFAs) (fig. S2, M and N). Down-regulation of RalGAP1 via small interfering RNA (siRNA) prevented OA-induced inactivation of RalA and RalB ( fig. S2L ). These data suggest that the RalGAP1/ complex might play a role in diet-induced muscle insulin resistance.
A RalGAP1
Thr735Ala knock-in mutation causes metabolic disorders in mice To address the in vivo role of Thr 735 phosphorylation of RalGAP1, we generated a RalGAP1
Thr735Ala knock-in mouse model using a gene-targeting strategy ( fig. S3 , A and B) in which the Thr 735 on RalGAPa1 was mutated to a nonphosphorylatable alanine residue. In skeletal muscle, the RalGAP1 Thr735Ala mutant protein was expressed at a level similar to the counterpart in wild-type (WT) mice (Fig. 1C) . Insulin stimulated Thr 735 phosphorylation on RalGAP1 in skeletal muscle of WT mice (Fig. 1C) . In contrast and as expected, Thr 735 phosphorylation of the mutant RalGAP1
Thr735Ala protein was undetectable in skeletal muscle of knock-in mice (Fig. 1C) . This knock-in mutation neither altered expression of RalGAP nor elicited any compensatory response in RalGAP2 in various tissues (Fig. 1C and fig. S3 , C to E). Furthermore, the knock-in mutation did not impair insulin-stimulated phosphorylation of PKB and its substrates AS160 (Akt substrate of 160 kDa, also known as TBC1D4) and GSK3 (glycogen synthase kinase 3) in skeletal muscle, white adipose tissue (WAT), and liver ( Fig. 1C and fig. S3, C and D ). These data demonstrate the suitability of RalGAP1
Thr735Ala knock-in mice and their derived tissues for studying the specific in vivo and in vitro role of RalGAP1-Thr 735 phosphorylation. We monitored the growth of RalGAP1
Thr735Ala knock-in mice and found that they weighed more than their WT littermates from the age of 10 weeks onward with normal food intake ( Fig. 1D and  fig. S3F ). Body composition analysis revealed that knock-in mice had a greater fat mass than WT mice from around 5.5 months (Fig. 1E) . Their adipocytes were also larger in size than WT cells (Fig. 1, F and G). At a young age (7 to 8 weeks old), knock-in mice had normal fasting blood glucose and plasma insulin levels, but their blood triglyceride (TG), free fatty acid (FFA), and total cholesterol (TC) were significantly elevated ( fig. S3G ). As the animals aged, fasting blood glucose and plasma insulin in RalGAP1
Thr735Ala knock-in mice were both significantly elevated from around 6 months of age (Fig. 1H) . Older knock-in mice still had higher blood TG and TC than their WT littermates (Fig. 1H) , and their hepatic TG and TC were also higher than those of WT littermates (Fig. 1I) , showing that knock-in mice developed nonalcoholic fatty liver disease (NAFLD). Together, these data demonstrate that the RalGAP1
Thr735Ala knock-in mutation causes metabolic disorders in mice, suggesting that RalGAP1-Thr 735 phosphorylation is critical for metabolic health.
Insulin-stimulated RalA activation, GLUT4 translocation, and glucose uptake are impaired in the RalGAP1
Thr735Ala knock-in skeletal muscle
We then sought to find out how the RalGAP1
Thr735Ala knockin mutation affected postprandial glycemic control. When orally gavaged with a bolus of glucose, knock-in mice were slower to clear blood glucose than their WT littermates at a young age (6 weeks old; fig. S3 , H and I) and at an older age (12 months old; Fig. 2A ). In agreement, they exhibited insulin resistance when intraperitoneally injected with insulin (Fig. 2B) . Our previous work showed that overexpression of a RalGAP1
Thr735Ala mutant protein inhibited insulin-stimulated GLUT4 translocation in cultured L6 myoblasts through suppressing RalA activation (13) . In agreement with these findings, insulin activated RalA in skeletal muscle of WT mice but not in RalGAP1
Thr735Ala knock-in mice (Fig. 2C ). GLUT4 protein was expressed at comparable levels in skeletal muscle from the two genotypes (Fig. 2D) . However, the insulin-stimulated translocation of GLUT4 to the cell surface was markedly decreased in the RalGAP1
Thr735Ala skeletal muscle ex vivo, compared with WT muscle, as assessed by immunoprecipitation of GLUT4 after cell surface proteins were biotinylated (Fig. 2, D 
and E). The impaired GLUT4 translocation in the RalGAP1
Thr735Ala skeletal muscle was further confirmed using a fluorescence assay, staining for GLUT4 on the plasma membrane (Fig. 2, F and G) . As a consequence of impaired GLUT4 translocation, insulin-stimulated glucose uptake was inhibited in the RalGAP1
Thr735Ala skeletal muscle ex vivo (Fig. 2, H and I ). In agreement with RalGAP1 being a minor form and RalGAP2 as a major form in the liver, WAT, and brown adipose tissue (BAT) ( fig. S3E ) (13) , the RalGAP1 Thr735Ala mutation did not affect RalA activation in response to insulin in these three tissues ( fig. S3 , K to M). Insulin-stimulated glucose uptake and GLUT4 translocation were normal in primary brown adipocytes and BAT from RalGAP1
Thr735Ala knock-in mice, respectively ( fig. S4 , A and C). Together, these data show that the RalGAP1
Thr735Ala knock-in mutation inhibited insulin-stimulated GLUT4 translocation and glucose uptake in skeletal muscle and thereby impaired postprandial glycemic control. knock-in male mice at 11 to 12 months of age. n = 13 to 14. Data are given as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
The RalGAP1
Thr735Ala knock-in mutation inhibits muscle lipid uptake and oxidation but does not affect hepatic output of TG We next investigated how the RalGAP1
Thr735Ala knock-in mutation caused hyperlipidemia in mice. We challenged mice with olive oil through oral gavage and monitored blood TG. RalGAP1 Thr735Ala knock-in mice had higher levels of TG in their blood, with significant increases of area under the curve (Fig. 3A) , suggesting that these animals were unable to efficiently clear blood lipids. Since skeletal muscle plays a critical role in postprandial lipid control, we suspected that muscle lipid uptake and/or oxidation might be impaired in RalGAP1 Thr735Ala knock-in mice. Insulin-stimulated lipid uptake was significantly (~30%) lower in the RalGAP1
Thr735Ala knock-in muscle than in WT muscle (Fig. 3B) . Moreover, insulin could no longer stimulate lipid oxidation in the knock-in muscle in contrast to causing a robust increase in the WT muscle (Fig. 3C) . Again, insulin-stimulated LCFA uptake remained normal in primary brown adipocytes from RalGAP1 Thr735Ala knock-in mice ( fig. S4B ). Secretion of TG-rich very-low-density lipoprotein (VLDL) from the liver into the blood provides an important source of TG to other tissues such as skeletal muscle. TG in the VLDL has to be hydrolyzed by lipoprotein lipase (LPL) to release FFAs for uptake by skeletal muscle. To examine whether hepatic output of TG might contribute to hyperlipidemia in the knock-in mice, we treated mice with an LPL inhibitor, tyloxapol, and monitored TG levels in the blood. Tyloxapol treatment elevated blood TG to similar levels in the two genotypes despite a higher level At least 100 muscle fibers were quantified per condition/genotype. Scale bars, 2 m. †P < 0.001 (WT insulin versus WT basal) and ‡P < 0.001 (RalGAP1 Thr735Ala insulin versus RalGAP1 Thr735Ala basal). (H and I) Glucose uptake in the soleus (H) or extensor digitorum longus (EDL) (I) muscle ex vivo of female WT and RalGAP1 Thr735Ala knockin mice (4 months old) in response to insulin. n = 6 to 8. Insulin-stimulated fold increases of glucose uptake were calculated rates in each genotype. †P < 0.01 (soleus) or P < 0.001 (EDL) (RalGAP1 Thr735Ala insulin versus WT insulin). Data are given as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001. of blood TG in the knock-in mice before treatment ( fig. S3J ), suggesting that hepatic output of TG most likely did not account for hyperlipidemia in knock-in mice. Together, these data show that muscle lipid uptake and oxidation were impaired in RalGAP1 Thr735Ala knockin mice, which might be the underlying cause for hyperlipidemia in these animals.
RalGAP1-Thr
735 phosphorylation regulates CD36 translocation via RalA in skeletal muscle in response to insulin We next studied the molecular mechanism by which the RalGAP1 Thr735Ala knock-in mutation inhibited muscle lipid uptake and oxidation. Uptake of lipids into skeletal muscle is the first rate-limiting step for lipid oxidation, and the mRNA levels of key regulators for muscle lipid uptake such as Cd36, Fatp1, and Fabp3 were normal in the RalGAP1
Thr735Ala knock-in skeletal muscle (Fig. 3D) . The protein level of the fatty acid translocase CD36, the major transporter mediating muscle lipid uptake, was also normal in the knock-in muscle (Fig. 3E ). Similar to GLUT4, CD36 is translocated from intracellular vesicular compartments onto the plasma membrane of muscle cells upon insulin stimulation and thus mediates uptake of lipids into skeletal muscle (14) . As expected, the cell surface content of CD36 was significantly increased in WT muscle in response to insulin (Fig. 3E ). Insulin-stimulated CD36 translocation was greatly inhibited in RalGAP1
Thr735Ala knock-in muscle compared with the corresponding control muscles (Fig. 3E) . In contrast, the RalGAP1
Thr735Ala mutation did not affect CD36 levels on the cell surface in BAT ( fig. S4C ). Lipid uptake is coupled with its oxidation in skeletal muscle through multiple mechanisms including up-regulation of key genes for lipid oxidation (15) . In agreement with inhibition of muscle LCFA uptake, we found that mRNA levels of key regulators of lipid oxidation, including Acox1, Cpt1, and Ppar, were significantly decreased in the skeletal muscle of RalGAP1
Thr735Ala knock-in mice (Fig. 3D ). Together, these data suggest that RalGAP1-Thr 735 phosphorylation regulates insulin-stimulated lipid uptake and oxidation in skeletal muscle via control of CD36 translocation.
To gain further insights into how RalGAP1 and its Thr 735 phosphorylation regulate CD36 translocation, we used L6 myotubes that were differentiated from myoblasts. Similar to skeletal muscle, insulin stimulated the translocation of CD36 onto the cell surface in L6 myotubes ( Fig. 3F and fig. S5A ). Down-regulation of RalGAP1 via siRNA markedly increased the CD36 content of the cell surface in response to insulin stimulation without altering total CD36 protein levels ( Fig. 3F and fig. S5A ). When RalA was down-regulated via siRNA, insulin no longer promoted CD36 translocation onto the cell surface in both WT and RalGAP1-knockdown L6 myotubes ( Fig. 3F and fig. S5B ). In contrast, knockdown of RalB had no effect on insulin-stimulated CD36 translocation in L6 myotubes ( fig. S5C) . Furthermore, RalA could be detected on CD36-containing vesicles when they were immunoprecipitated from L6 myotubes (Fig. 3G) . Immunostaining of RalA and CD36 showed that these two proteins were partially colocalized in muscle fibers (Fig. 3H) . Insulin did not appear to affect the association of RalA with CD36-containing vesicles ( fig. S5, D and E) . These data show that the RalGAP1-RalA axis, but not the RalGAP1-RalB axis, regulates CD36 translocation in skeletal muscle cells.
Overexpression of RalGAP1 Thr735Ala mutant protein prevented insulin-stimulated CD36 translocation in L6 myotubes (Fig. 3I and  fig. S5F ), which resembled the inhibitory effect of RalGAP1 Thr735Ala knock-in mutation on CD36 translocation in skeletal muscle. Asn 1949 is a critical residue for the GAP activity of RalGAP1, and a lysine substitution of Asn 1949 can inactivate this GAP activity (8) and counteract the inhibitory effect of RalGAP1 Thr735Ala mutation on RalA activation in response to insulin (13) . This Asn
1949
Lys substitution also relieved the inhibitory effect of RalGAP1 Thr735Ala mutation on insulin-stimulated CD36 translocation (Fig. 3I) . Moreover, overexpression of a constitutively active RalA Gly23Val mutant and WT RalA relieved the inhibitory effect of RalGAP1
Thr735Ala mutation on insulinstimulated CD36 translocation (Fig. 3J and fig. S5G ). Together, these data demonstrate that insulin-stimulated RalGAP1-Thr 735 phosphorylation inactivates its GAP activity and promotes CD36 translocation in muscle cells through activation of RalA.
Expression of lipogenic genes is up-regulated in the WAT of RalGAP1
Thr735Ala knock-in mice probably because of systemic signals The obesity of RalGAP1
Thr735Ala knock-in mice prompted us to investigate whether lipid metabolism is altered in the WAT. To avoid potential complications from obesity, we studied tissues from animals at 2 months of age when RalGAP1
Thr735Ala knock-in mice were not yet obese (Fig. 1D) . Adipogenic genes such as Cebp and Ppar and lipolysis gene Atgl were expressed normally, while lipogenic genes such as Fasn and Acc1 were significantly up-regulated in the WAT of knock-in mice ( fig. S4D ). However, these lipogenic genes were not up-regulated in primary adipocytes isolated from RalGAP1 Thr735Ala knock-in mice ( fig. S4E ), suggesting that systemic signals induced expression of these lipogenic genes. In agreement with previous reports (16), we found that OA could induce lipogenic gene expression in primary adipocytes ( fig. S4F ). Given that RalGAP1
Thr735Ala knock-in mice had hyperlipidemia before they developed obesity (Fig. 1D and fig.  S3G ), these data suggest that hyperlipidemia might account for the up-regulation of lipogenic genes in the WAT.
Muscle-specific deletion of RalGAP1 activates RalA and RalB in skeletal muscle
To further unravel roles of the RalGAP1-Ral axis in insulin action and resistance in skeletal muscle, we generated a skeletal musclespecific RalGAP1 knockout (RalGAP1-mKO) mouse model through mating RalGAP1 f/f with Mlc1f-Cre mice that express the Cre recombinase in a knock-in manner under the control of the myosin light chain 1f genomic locus (17) . As anticipated, RalGAP1 protein was greatly decreased in skeletal muscle of RalGAP1-mKO mice but not in other tissues examined, including the BAT, where RalGAP1 is a minor form (Fig. 4A and fig. S6 , A and C). This Mlc1f-Cre was expressed in all types of skeletal muscle examined, including the soleus, extensor digitorum longus (EDL), tibialis anterior, and gastrocnemius muscles ( fig. S6B ), which decreased RalGAP1 expression in these muscles (Fig. 4A and  fig. S6C ). RalGAP1 deficiency caused destabilization of the regulatory subunit RalGAP in skeletal muscle (Fig. 4A and fig. S4C ). RalGAP2 protein was expressed at a low level in WT skeletal muscle, and no apparent compensatory change in its expression was observed in RalGAP1-mKO mice (Fig. 4A) . The increased phosphorylation of PKB, and its substrates AS160 and GSK3, in response to insulin in the RalGAP1-mKO mice was similar to that in the RalGAP1 f/f (WT) littermate controls (Fig. 4B) . Active RalA and RalB levels were markedly increased in the RalGAP1-mKO skeletal muscle under both basal and insulin-stimulated conditions, while total RalA and RalB protein levels remained normal (Fig. 4, C and D, and fig. S6, D and E) .
In agreement with the proposed role of RalB in the regulation of mTORC1 (12) , deletion of RalGAP1 both activated the mTORC1-S6K axis and increased IRS1-Ser 307 phosphorylation in skeletal muscle ( fig. S6, F and G) . Although RalB was inactivated by an HFD in skeletal muscle, the mTORC1-S6K axis was activated in skeletal muscle of HFD-fed mice ( fig. S6, F and G) , probably because of activation of mTORC1 by FFAs (18) . Moreover, HFD and deletion of RalGAP1 displayed no additive effects on the activation of the Data are given as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
mTORC1-S6K axis and phosphorylation of IRS1-Ser 307 ( fig. S6 , F and G).
Muscle-specific deletion of RalGAP1 improves postprandial glycemic and lipid control
We next sought to find out how deletion of RalGAP1 in skeletal muscle affected postprandial glycemic and lipid control. Blood glucose and plasma insulin were normal in RalGAP1-mKO mice fed with a chow diet ( fig. S6H) . However, when administered with a bolus of glucose via oral gavage, RalGAP1-mKO mice cleared blood glucose more quickly than their corresponding WT littermate controls (Fig. 4E) . When mice were fed on an HFD, RalGAP1-mKO mice developed obesity at rates similar to that of WT littermates ( fig. S6I ). When fed an HFD, RalGAP1-mKO mice still cleared blood glucose faster than their WT littermates after being challenged with a bolus of glucose (Fig. 4F) . Under the HFD condition, RalGAP1-mKO mice had a moderate decrease in their blood glucose and a significant decrease in their plasma insulin (Fig. 4H) .
In contrast to RalGAP1 Thr735Ala knock-in mice, RalGAP1-mKO mice had lower fasting blood TG levels than their WT littermates under conditions of both normal chow diet and HFD (Fig. 4 , G and H), although they still developed obesity on an HFD. Deletion of RalGAP1 in skeletal muscle also lowered fasting blood FFA in mice on a chow diet and an HFD (Fig. 4, G and H) . Again, hepatic output of TG was unlikely to be the underlying cause for low blood lipids in RalGAP1-mKO mice, since tyloxapol elevated blood TG to similar levels in RalGAP1-mKO and control mice (Fig. 4I ). When administered with an oral load of olive oil, RalGAP1-mKO mice exhibited an improved ability to control blood lipids, as evidenced by smaller areas under the curve for both blood TG and FFA (Fig. 4 , J and K).
Together, these data suggest that the RalGAP1-RalA axis may have a dominant effect on muscle insulin sensitivity over the RalGAP1-RalB axis and also demonstrate that deletion of RalGAP1 in skeletal muscle improves postprandial glycemic and lipid control.
Insulin-stimulated uptake of glucose and LCFAs were enhanced in the RalGAP1-deficient skeletal muscle
We next examined the impacts of RalGAP1 deficiency on muscle glucose and lipid metabolism. Under basal conditions, glucose uptake in isolated soleus and EDL muscles displayed no difference between WTs and RalGAP1 knockouts (Fig. 5, A and B) . In both isolated soleus and EDL muscles, insulin-stimulated glucose uptake was ~20% higher in the RalGAP1 knockouts than in WTs, resulting in a greater insulin response in RalGAP1-deficient muscle (Fig. 5, A and B) . GLUT4 protein was expressed at similar levels in the RalGAP1-mKO and WT muscle (Fig. 5C ). The insulin-stimulated activation of PKB was again comparable between the two genotypes in isolated muscle ex vivo (Fig. 5C ). In the basal state, GLUT4 levels on cell surface were comparable in skeletal muscle between WTs and RalGAP1 knockouts (Fig. 5C ), suggesting that RalA activation alone due to RalGAP1 deficiency was insufficient to promote GLUT4 translocation under basal conditions. Other factors such as AS160 might contribute to intracellular retention of GLUT4 in RalGAP1-deficient skeletal muscle under basal conditions (19) . After insulin stimulation, cell surface GLUT4 contents were higher in the RalGAP1-deficient muscle than in the WT muscle (Fig. 5C ). In agreement with intact RalGAP1 expression in the BAT of RalGAP1-mKO mice ( fig. S6C ), insulin-stimulated RalA activation in the BAT and glucose uptake in primary brown adipocytes were both normal in the RalGAP1-mKO mice ( fig. S6 , J to L).
Similar to muscle glucose uptake, insulin-stimulated LCFA uptake was significantly higher in RalGAP1-mKO skeletal muscle than in the corresponding WT control (Fig. 5D) . In parallel, insulin-stimulated lipid oxidation was also augmented in the RalGAP1-mKO skeletal muscle (Fig. 5D) . Again, insulin-stimulated LCFA uptake remained normal in primary brown adipocytes from RalGAP1-mKO mice ( fig. S6M) . The mRNA levels of key regulators for muscle lipid uptake, namely, Cd36, Fatp1, and Fabp3, were unchanged in the RalGAP1-mKO skeletal muscle as compared to their corresponding control tissues (Fig. 5E) . Moreover, CD36 protein levels were also normal in RalGAP1-mKO skeletal muscle (Fig. 5F ). As expected, cell surface CD36 contents were significantly increased in the WT muscle in response to insulin (Fig. 5F ). Insulin-stimulated CD36 translocation was markedly increased in the RalGAP1-deficient skeletal muscle as compared with the corresponding control muscles (Fig. 5F ). The mRNA levels of key regulators for muscle lipid oxidation, namely, Acox1, Cpt1, and Ppar, were up-regulated in the RalGAP1-mKO skeletal muscle, as compared to their corresponding control tissues (Fig. 5E) , which was probably due to the increase of muscle lipid uptake.
Together, these data show that increases in insulin-stimulated muscle uptake of glucose and LCFAs may account for the improvements of postprandial glycemic and lipid control in RalGAP1 muscle-specific knockout mice.
A RalGAP-derived peptide could eliminate RalGAP1 and improve insulin sensitivity in muscle cells
We next sought to develop a peptide blockade to interfere with RalGAP1 for improving insulin sensitivity in muscle cells. The RalGAP1 and RalGAP subunits form a protein complex to exert its GAP function. We therefore postulated that certain RalGAP-derived peptide(s) might block formation of the RalGAP1/ complex. To this end, we first mapped the region(s) on RalGAP1 that interacts with RalGAP and identified two regions on RalGAP1, namely, M1-T589 and Q1755-End ( fig. S7, A to D (Fig. 6, A and B) . We therefore named this RalGAP E1121-T1158 -blockade peptide (shorted to -blockatide). Moreover, expression of -blockatide also diminished endogenous RalGAP1 but not RalGAP in L6 myotubes without affecting their mRNA levels (Fig. 6, C and D, and fig. S8A ). The -blockatide-induced decrease of RalGAP1 was dependent on the proteasomal degradation pathway and was prevented by the proteasome inhibitor N-carbobenzyloxy-l-leucyl-l-leucyl-l-leucinal ( fig. S8 , B and C). Furthermore, -blockatide could disrupt the interaction between RalGAP1 and RalGAP ( fig. S8, B and D) . Expression of -blockatide enhanced insulin-stimulated RalA activation and translocation of GLUT4 and CD36 in L6 myotubes (Fig. 6, E, F, H, and I) . Moreover, expression of -blockatide significantly increased uptake of glucose and LCFAs in L6 myotubes in response to insulin stimulation (Fig. 6, G and J) .
DISCUSSION
Our findings shed light on how RalGAP1 functions as a critical node in insulin signaling to participate in insulin action and resistance in skeletal muscle. Our results demonstrate that RalGAP1 is critical for insulin action in skeletal muscle and are consistent with a model in which phosphorylation of RalGAP1-Thr 735 by PKB controls whole-body glucose and lipid homeostasis at least in part through regulating insulin-governed muscle uptake of glucose and LCFAs via RalA (Fig. 6K) . Elevation of nonphosphorylated RalGAP1 contributes to the development of muscle insulin resistance induced by HFDs, and targeting RalGAP1 may be a promising strategy to improve muscle insulin sensitivity.
In the current view, serine phosphorylation of IRS is central for the development of insulin resistance in diet-induced obesity (6) . The up-regulation of nonphosphorylated RalGAP1 in skeletal muscle of HFD-induced obese mice may represent a previously unidentified mechanism for muscle insulin resistance, which is complementary to the IRS-centric mechanism. In this scenario, the HFD-induced up-regulation of nonphosphorylated RalGAP1 results in inactivation of RalA, which consequently renders skeletal muscle unable to absorb glucose and LCFAs in response to insulin. The inhibitory effect on insulin action exerted by the obesity-driven RalGAP1-RalA axis may overwhelm the opposing effect of the RalGAP1-RalB axis to alleviate feedback regulation of IRS, tipping the balance toward dampening glucose and LCFA uptake into skeletal muscle in dietinduced obesity. Furthermore, fatty acids can activate a number of kinases, including mTOR, S6K, JNK, and PKC, to phosphorylate IRS serine residues (6), which also counteract the alleviating effect of RalB (H and I) Cell surface and total CD36 levels in L6 myotubes expressing the -blockatide in response to insulin. Quantitative data of cell surface CD36 that were normalized to total CD36 were shown in (I), in which basal surface CD36 levels were quantified using dark exposure and insulin-stimulated surface CD36 levels were quantified using light exposure. n = 3. (J) Uptake of LCFAs (BODIPY 558/568 C12) in L6 myotubes expressing the -blockatide in response to insulin. n = 6. †P < 0.001 (vector control insulin versus vector control basal) and ‡P < 0.001 (-blockatide insulin versus -blockatide basal). (K) A working model for the RalGAP1/ complex as a key node in muscle insulin signaling. In insulin-sensitive muscles, insulin can inactivate the RalGAP1/ complex via phosphorylation of RalGAP1, thereby resulting in activation of RalA. The latter can then increase muscle uptake of glucose and LCFAs via promoting translocation of GLUT4 and CD36. In insulin-resistant muscles, the nonphosphorylated RalGAP1/ complex is elevated and inactivates RalA, which consequently inhibits muscle uptake of glucose and LCFAs. The -blockatide can disrupt the RalGAP1/ complex and cause proteasomal degradation of RalGAP1, which consequently increases muscle insulin sensitivity. PI3K, phosphatidylinositol 3-kinase. Data are given as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
inactivation by induction of RalGAP1 in obesity. Thus, the RalGAP1-RalA axis may play a critical role in the development of dietinduced insulin resistance, while the RalGAP1-RalB axis may only have a marginal effect on HFD-induced IRS serine phosphorylation. This notion is supported by our observation of improved postprandial glucose and lipid control in the RalGAP1-mKO mice under HFD conditions. Skeletal muscle has been emerging as an important player in regulating whole-body metabolic homeostasis in recent years, although its potential for treatment of metabolic diseases has not been fully appreciated (3, 20, 21) . Lack of suitable molecular targets impedes the development of drugs targeting skeletal muscle to treat metabolic diseases. Our findings therefore provide a conceptual demonstration that RalGAP1 in skeletal muscle might be a possible target for antidiabetic drugs. Overload of LCFAs in skeletal muscle can lead to serine phosphorylation of IRS and cause insulin resistance (22, 23) . The position of RalGAP1 in insulin signaling endows its inactivation as a potential therapeutic strategy with a unique dual-action feature. Inactivation of RalGAP1 in skeletal muscle can decouple LCFA uptake and serine phosphoryl ation of IRS from lipid inhibition of insulin action on muscle glucose uptake and thus simultaneously improve postprandial glucose and lipid control. Our -blockatide may be used as a prototype for the development of small molecules to target RalGAP1 for improving muscle insulin sensitivity. It is currently unclear why overload of LCFAs in muscle cells increases protein levels of the RalGAP1/ complex, which deserves further investigations of translational/posttranslational effects and protein stability in the future.
In contrast to the RalGAP1/ complex being dominant in skeletal muscle, RalGAP2/ is the major complex in the WAT (13) and in the BAT (this study). A recent study shows that adipose tissuespecific deletion of RalGAP results in activation of RalA in both WAT and BAT (24) . Deletion of RalGAP in the adipose tissues protects mice from development of metabolic disease due to increased glucose uptake into the BAT (24) . These studies highlight the importance of both RalGAP1/ and RalGAP2/ complexes in metabolic health, although they function in distinct tissues. The evolution of these two protein complexes may diversify regulatory mechanisms for metabolic control in different tissues through RalA.
AS160 is another known regulator of insulin-stimulated GLUT4 trafficking (25) . It is a functional GAP for Rab small GTPase and mediates intracellular retention of GLUT4. AS160 can be phospho rylated by PKB on its Thr 642 site, which inhibits its GAP activity and consequently promotes GLUT4 translocation in response to insulin. Similar to the RalGAP1 Thr735Ala knock-in mutation, an AS160 Thr642Ala knock-in mutation also impairs insulin-stimulated GLUT4 translocation and causes muscle insulin resistance in mice (26) . Despite these similarities, these two knock-in mice display some distinct metabolic phenotypes. RalGAP1
Thr735Ala knock-in mice developed hyperlipidemia, obesity, and NAFLD even on a normal chow diet. In contrast, AS160
Thr642Ala knock-in mice have normal blood lipid levels and body weight (26) . Moreover, unlike the RalGAP1 deletion that improved glycemic control in mice, AS160 deletion in mice or null mutation in human patients causes insulin resistance due to an effect in decreasing GLUT4 protein levels in skeletal muscle (20, 21, 27, 28) . More needs to be done in the future to get a better understanding of the molecular mechanisms underlying the different metabolic changes caused by mutations of RalGAP1 and AS160.
GAPs and guanine nucleotide exchangers (GEFs) are critical upstream regulators of their target small G proteins and can also be downstream effectors of small G proteins, thus forming small G protein cascades (29) . For instance, the active GTP-bound Rab10 can bind to the RalA GEF RalGDS-like factor (Rlf) and increase its activity in adipocytes. Consequently, Rlf promotes RalA to become a GTP-loaded active form that mediates glucose uptake into the adipocytes in response to insulin (30) . There are seven RalA GEFs in humans (31) , and it is currently unknown which one of them mediates insulin-stimulated RalA activation in skeletal muscle. Knockout of RalGAP1 in skeletal muscle does not result in a full activation of RalA in the basal state, suggesting that such a RalA GEF might also be regulated by insulin in skeletal muscle. Rab8a has recently been identified as a critical regulator for the translocation of GLUT4 and CD36 in skeletal muscle cells (3, 32) . Therefore, an intriguing question is whether a small G protein cascade involving Rab8a and RalA exists to regulate translocation of GLUT4 and CD36 in skeletal muscle.
Exercise has been widely used as an antidiabetic therapeutic, whose beneficial effect is in part mediated by up-regulation of glucose utilization in skeletal muscle (33) . Exercise-induced energy stress can activate the energy sensor adenosine 5′-monophosphate-activated protein kinase (AMPK) that consequently regulates GLUT4 translocation and glucose uptake in skeletal muscle (34, 35) . Chemical AMPK activators such as the antidiabetic drug metformin and 5-aminoimidazole-4-carboxamide-1--d-ribofuranoside (AICAR) can also stimulate muscle glucose uptake via promoting GLUT4 translocation (36, 37) . TBC1D1 is a RabGAP that can be phosphorylated on its Ser 231 by AMPK (38) . TBC1D1-Ser 231 phosphorylation mediates AICARinduced GLUT4 translocation and glucose uptake in skeletal muscle but is dispensable for exercise-induced muscle glucose utilization (39) . How AMPK regulates exercise-induced muscle glucose uptake is still not clear. RalGAP1 can also be phosphorylated in response to exercise/ muscle contraction (13) . Given the critical role of RalGAP1 in insulinstimulated muscle glucose utilization, it would be intriguing to find out whether it might mediate the beneficial effects of exercise and metformin through controlling GLUT4 translocation and glucose uptake in skeletal muscle. Exercise can also enhance fatty acid utilization in skeletal muscle via promoting CD36 translocation (40) , which raises a further interesting question of whether RalGAP1 is involved in exercise-induced CD36 translocation in skeletal muscle. Although AMPK mediates the beneficial effects of exercise on metabolic control, chronic activation of AMPK with an AMPK activator MK-8722 causes cardiac hypertrophy in rodents and monkeys (41) . Therefore, it would be interesting to find out whether RalGAP1 might regulate cardiac function and whether the -blockatide might interfere with cardiac performance.
In summary, we demonstrate that RalGAP1 is a critical node in muscle insulin signaling and plays an important role in the development of muscle insulin resistance. RalGAP1 in skeletal muscle may be a possible therapeutic target for simultaneous improvement of postprandial glucose and lipid control in T2D.
MATERIALS AND METHODS

Materials
Recombinant human insulin was bought from Novo Nordisk (Denmark). HFD (60 kcal% fat; catalog no. 12492) was bought from Research Diets (USA). Sulfo-NHS-SS-Biotin, NeutrAvidin Agarose, and protein molecular markers were from Thermo Fisher Scientific (USA). Protein G Sepharose was from GE Healthcare (UK). 2-deoxy-d- [1,2- table S1 . Rabbit anti-CD36 was used for immunoblotting and immunoprecipitation, while mouse anti-CD36 was used for immunostaining. The pThr 735 -RalGAP1 antibody was originally produced using a pThr 715 peptide derived from RalGAP2 as described previously (9) and provided by X. Chen (Peking University, China).
Molecular biology
Cloning, fragmentation, and point mutation of the mouse RalGAP1, RalGAP, and RalA were carried out using standard procedures. All DNA constructs were sequenced by Life Technologies (Shanghai, China).
Generation of RalGAP1
Thr735Ala , RalGAP1 f/f , and muscle-specific RalGAP1 knockout mice RalGAP1
Thr735Ala knock-in mice on a C57BL/6J background were generated using the strategy outlined in fig. S3A by the transgenic facility at Nanjing University, in which the Thr 735 (the surrounding sequence is PMRQRSAtTTGSPGT; Thr 735 is shown in lower case bold) on RalGAP1 was changed to alanine via knock-in mutagenesis. The RalGAP1 knockout-first embryonic stem cells (cell line: JM8A3. N1; clone: EPD0573_2_A12) were purchased from the Knockout Mouse Project Repository (University of California Davis, USA) and used for blastocyst injection to generate RalGAP1 f/f mice. The sixth exon of RalGAP1 was flanked by two loxP sites in RalGAP1 f/f mice that were backcrossed to C57BL/6J background for at least five generations before the experiments. RalGAP1 f/f mice were mated with Mlc1f-Cre mice on a C57BL/6J background to obtain skeletal musclespecific RalGAP1 knockout (RalGAP1-mKO) mice.
Mouse breeding and husbandry
The animal facility at Nanjing University is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. The Ethics Committee at Nanjing University approved all animal studies and protocols. Mice were raised under a light/ dark cycle of 12 hours and had free access to food and water unless stated. Mating of RalGAP1 f/f with RalGAP1 f/f -Mlc1f-Cre generated RalGAP1 f/f (control mice) and RalGAP1 f/f -Mlc1f-Cre (RalGAP1-mKO) mice. As for RalGAP1
Thr735Ala knock-in mice, Het × Het mating was set up to generate homozygous knock-ins and WT littermates. RalGAP1 Thr735Ala knock-in mice were genotyped via polymerase chain reaction (PCR) using the following primers: 5′-CCTCTGC-CCTAAGTGTAACTG-3′ and 5′-TGAGGCTTTGTGGGCTGCTA-3′. Genotyping of RalGAP1 f/f mice was performed using the following primers: 5′-GAGATGGCGCAACGCAATTAATG-3′ and 5′-GGCT-GCAAAGAGTAGGTAAAGTGCC-3′. The Cre mice were genotyped using the following primers: 5′-GCCTGCATTACCGGTCGATGC-3′ and 5′-CAGGGTGTTATAAGCAATCCC-3′.
Blood chemistry
Blood glucose was measured using a Breeze2 glucometer (Bayer). Serum FFA, TG, and TC were measured using the Wako LabAssay NEFA kit (catalog no. 294-63601), LabAssay Triglyceride kit (catalog no. 290-63701), and LabAssay Cholesterol kit (catalog no. 294-65801) (Wako Chemicals, USA), respectively.
Oral glucose tolerance test and insulin tolerance test
Oral glucose tolerance test was carried out in mice deprived of food overnight (16 hours). A bolus of glucose (1.5 mg/g) was administered via oral gavage, and mice were tail-bled for measurement of blood glucose using a Breeze2 glucometer. As for insulin tolerance test, mice were intraperitoneally injected with insulin (0.75 mU/g) after being restricted from food access for 4 hours, and blood glucose was subsequently determined through tail bleeding.
Measurement of liver TG and TC
Liver TG was measured through determination of its glycerol contents, as previously described (42) . Briefly, saponification of frozen liver chunks was carried out in ethanolic KOH to release free glycerol that was measured using the Free Glycerol Reagent (catalog no. F6428, Sigma-Aldrich). For liver TC measurement, lipids were first extracted using an organic solvent consisting of chloroform:isopropanol: NP-40 (7:11:0.1). After removal of the organic solvent, TC in the extracts was then determined using the LabAssay Cholesterol kit (catalog no. 294-65801, Wako Chemicals, USA).
Muscle incubation and glucose uptake ex vivo
Muscle glucose uptake was carried out in isolated soleus or EDL muscles, as previously described (26) . Briefly, isolated soleus or EDL muscles were stimulated with or without insulin for 50 min and then incubated in Krebs-Ringer-bicarbonate (KRB) buffer containing 2-deoxy-d- [1, [2] [3] 
H(N)]glucose and d-1-[
14 C]mannitol for another 10 min with or without insulin. After incubation, the uptake assay was terminated in ice-cold KRB buffer containing cytochalasin B, and muscles were blotted dry, weighed, and lysed. 3 H and 14 C radioisotopes in muscle lysates were subsequently measured using a Tri-Carb 2800TR scintillation counter (PerkinElmer) for calculation of muscle glucose uptake.
Glucose uptake in primary adipocytes and L6 myotubes
Glucose uptake was carried out in primary adipocytes and L6 myotubes, as previously described (20) . Briefly, cells were deprived of serum and then treated with or without insulin for 30 min. Glucose uptake was carried out in Hepes-buffered saline buffer containing 2-deoxy-d-[1,2-3 H(N)]glucose in the presence or absence of insulin for 10 min. Radioisotopes in cell lysates were measured using the Tri-Carb 2800TR scintillation counter for calculation of glucose uptake rates.
Lipid uptake and oxidation
Lipid uptake and oxidation in isolated soleus was measured, as previously described (3) . Briefly, the soleus muscle was isolated and stimulated with or without insulin for 30 min. After insulin stimulation, the soleus muscle was incubated in KRB buffer (±insulin) containing 14 C-palmitic acid for 50 min. At the completion of incubation, 14 C radioisotopes within muscles were determined using the Tri-Carb 2800TR scintillation counter. After removal of muscle, perchloric acid (0.6 M) was added into incubation media to evolve gaseous 14 CO 2 that was subsequently trapped in benzethonium hydroxide-soaked filters and determined by scintillation counting. Muscle lipid oxidation was calculated using the radioactivity in gaseous 14 CO 2 . Muscle lipid uptake was calculated using the sum of radioactivity in muscle and gaseous 14 CO 2 . Lipid uptake in primary adipocytes and L6 myotubes was measured as previously described with modifications (43) . Briefly, cells were stimulated with or without insulin for 30 min. After insulin stimulation, cells were incubated in KRB buffer (±insulin) containing BODIPY 558/568 C12 (D-3835, Thermo Fisher Scientific) for 10 min. At the completion of incubation, BODIPY 558/568 C12 in cell lysates was determined using a microplate reader (Synergy H1, BioTek Instruments Inc.).
Measurements of cell surface GLUT4 and CD36
GLUT4 and CD36 on the cell surface were determined via a modified biotinylation method described previously (3) . Briefly, isolated soleus muscle or L6 myotubes were stimulated with or without insulin for 50 min and then incubated in KRB buffer (±insulin) containing Sulfo-NHS-SS-Biotin (1 mg/ml) (Thermo Fisher Scientific) for 30 min. After biotinylation of cell surface proteins, the soleus muscle or L6 myotubes were rinsed with 50 mM tris-HCl buffer (pH 8.0) twice to remove free Sulfo-NHS-SS-Biotin. After lysis, tissue/cell lysates were incubated with NeutrAvidin Agarose (Thermo Fisher Scientific) at 4°C overnight. After incubation, the beads were washed three times with the ice-cold phosphate-buffered saline buffer containing 1% NP-40 to remove nonspecific binding proteins. Afterward, biotinylated cell surface proteins were eluted in SDS sample buffer at room temperature for 30 min and subjected to immunoblotting analysis. Biotinylated GLUT4 and CD36 were detected using corresponding specific antibodies.
Cell culture, transfection, and lysis HEK293 cells were purchased from the Cell Resource Center, Chinese Academy of Medical Sciences and Peking Union Medical College (China). Rat L6 myoblasts were provided by A. Klip (University of Toronto, Canada). HEK293 cells and L6 myoblasts were maintained in Dulbecco's modified Eagle's medium containing 10% (v/v) fetal bovine serum and regularly tested for mycoplasma contamination. L6 myoblasts were differentiated into myotubes, as previously described (38) . Transfection of HEK293 cells or L6 myotubes with plasmid DNA or siRNA was performed using a Lipofectamine 3000 reagent (Thermo Fisher Scientific). Two days after transfection, cells were lysed, as previously described (42) .
Primary white preadipocytes were isolated, cultured, and differentiated into white adipocytes, as previously described (20) . Primary brown preadipocytes were isolated, cultured, and differentiated into brown adipocytes, as previously described (44) .
Measurements of GTP-bound form of RalA and RalB
Levels of GTP-bound form of RalA or RalB were measured via a pull-down assay, as previously described (13) . Briefly, mouse tissues or L6 muscle cells were lysed in lysis buffer [50 mM Hepes/KOH (pH 7.4), 100 mM NaCl, 4 mM MgCl 2 , 1 mM dithiothreitol, 1% NP-40, 10% glycerol, 10 mM NaF, 1 mM Na 3 VO 4 , leupeptin (1 g/ml), pepstatin (1 g/ml), and aprotinin (1 g/ml)]. Purified recombinant glutathione S-transferase-Sec5N (1 to 120 amino acids) protein was immobilized on glutathione Sepharose beads and incubated with tissue/cell lysates at 4°C for 1 hour. After removal of nonspecific binding proteins via intensive washing of resins, the active RalA or RalB that was bound to Sec5N was eluted off from the resins in SDS sample buffer and detected via immunoblotting.
Tissue lysis and protein measurement
Mouse tissues were harvested, snap-frozen in liquid nitrogen, and homogenized, as previously described (26) . Protein contents of tissue lysates were determined using Bradford reagent (Thermo Fisher Scientific).
Immunoprecipitation and immunoblotting
Immunoprecipitation of target proteins was performed, as previously described (42) . Briefly, tissue or cell lysates were incubated with the antibody-coupled protein G Sepharose or GFP-binder (ChromoTek GmbH, Planegg-Martinsried, Germany) at 4°C overnight. After intensive washing to remove nonspecific binding proteins, immunoprecipitates were eluted in SDS sample buffer (42) .
As for immunoprecipitation of CD36-containing vesicles, L6 myotubes were lysed in a detergent-free lysis buffer via passing through a 22-gauge needle (12 times) and a 27-gauge needle (6 times). Unbroken cells were removed via centrifugation at 500g for 10 min. Plasma membrane, mitochondria, nuclei, and high-density microsomes were removed via centrifugation at 15,750g for 17 min. Lysates containing low-density microsomes were incubated with rabbit anti-CD36 or preimmune immunoglobulin G overnight at 4°C. Afterward, protein G Sepharose was added and incubated for 1 hour at 4°C. The beads were washed three times with detergent-free lysis buffer to remove nonspecific binding proteins/low-density microsomes. Immunoprecipitates were then eluted in SDS sample buffer.
Tissue/cell lysates or immunoprecipitates were separated via SDSpolyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes, and subjected to immunoblotting assay, as previously described (42) . Quantification of immunoblotting signals was carried out using ImageJ and expressed as fold changes. Phosphorylation signals were normalized with corresponding total proteins.
Immunofluorescence staining and imaging
Immunofluorescence staining was carried out, as previously described (3). Briefly, paraformaldehyde-fixed muscle fibers were sequentially probed with primary antibodies and Alexa Fluor-conjugated or Cy3/ Cy5-conjugated secondary antibodies. Images were taken with a Leica confocal microscope. Colocalization of CD36 and RalA was assessed via Manders' overlap coefficient (R) using Image-Pro Plus software.
Real-time quantitative PCR
Real-time quantitative PCR was carried out to measure expression levels of target genes using an Applied Biosystems StepOnePlus system. The primers for real-time quantitative PCR are listed in table 2.
Statistical analysis
Data are given as means ± SEM. Comparisons were performed via t test for two groups or via two-way analysis of variance (ANOVA) for multiple groups using Prism software (GraphPad, San Diego, CA, USA).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/5/4/eaav4116/DC1 Table S1 . The list of antibodies used in this study. Table S2 . Primer information for quantitative real-time fluorescence PCR analysis of expression of target genes. Fig. S1 . Specificity of the pT735-RalGAP1 antibody. Fig. S2 . Effects of HFD/fatty acids on the RalGAP1/ complex and RalA/B activities in skeletal muscle and L6 myotubes. Thr735Ala knock-in mice. Fig. S4 . Uptake of glucose and LCFAs and expression of genes for lipid metabolism in adipose tissues and primary adipocytes. Fig. S5 . Cell surface and total CD36 in L6 myotubes. Fig. S6 . Characterization of RalGAP1-mKO mice. Fig. S7 . Mapping of interaction domains on RalGAP1 and RalGAP. Fig. S8 . Expression, degradation, and interaction of RalGAP1 and RalGAP in L6 myotubes expressing -blockatide.
